AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics


AcelRx Pharmaceuticals, Inc. (ACRX): $1.18

-0.02 (-1.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACRX POWR Grades


  • Growth is the dimension where ACRX ranks best; there it ranks ahead of 55.47% of US stocks.
  • ACRX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • ACRX ranks lowest in Stability; there it ranks in the 1st percentile.

ACRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ACRX is -0.2 -- better than just 5.94% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.43 for Acelrx Pharmaceuticals Inc; that's greater than it is for just 5.2% of US stocks.
  • Revenue growth over the past 12 months for Acelrx Pharmaceuticals Inc comes in at 129.92%, a number that bests 95.22% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Acelrx Pharmaceuticals Inc are BGMD, NVCN, BQ, BXRX, and KMPH.
  • ACRX's SEC filings can be seen here. And to visit Acelrx Pharmaceuticals Inc's official web site, go to www.acelrx.com.

ACRX Valuation Summary

  • ACRX's EV/EBIT ratio is -4.5; this is 116.85% lower than that of the median Healthcare stock.
  • Over the past 127 months, ACRX's price/sales ratio has gone NA NA.
  • Over the past 127 months, ACRX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ACRX.

Stock Date P/S P/B P/E EV/EBIT
ACRX 2021-01-25 42.3 -3.8 -4.8 -5.3
ACRX 2016-08-24 6.1 11.2 -5.5 -3.1
ACRX 2014-08-27 11.1 5.7 -23.4 -22.2
ACRX 2014-02-24 141.9 9.5 -9.8 -9.1
ACRX 2013-04-11 92.9 6.6 -6.7 -6.1
ACRX 2013-02-22 89.9 -369.1 -4.1 -5.0

ACRX Growth Metrics

  • Its 3 year revenue growth rate is now at -90.62%.
  • The year over year cash and equivalents growth rate now stands at 43.86%.
  • Its 2 year revenue growth rate is now at -53.91%.
Over the past 67 months, ACRX's revenue has gone down $12,037,000.

The table below shows ACRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 5.541 -33.849 -33.41
2020-12-31 5.416 -38.505 -40.379
2020-09-30 5.153 -46.333 -45.884
2020-06-30 4.393 -49.675 -49.685
2020-03-31 2.41 -52.304 -55.491
2019-12-31 2.289 -51.18 -53.24

ACRX Price Target

For more insight on analysts targets of ACRX, see our ACRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.67 Average Broker Recommendation 1.33 (Strong Buy)

ACRX Stock Price Chart Interactive Chart >

Price chart for ACRX

ACRX Price/Volume Stats

Current price $1.18 52-week high $2.94
Prev. close $1.20 52-week low $1.02
Day low $1.16 Volume 719,600
Day high $1.20 Avg. volume 3,862,091
50-day MA $1.35 Dividend yield N/A
200-day MA $1.58 Market Cap 140.54M

AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.


ACRX Latest News Stream


Event/Time News Detail
Loading, please wait...

ACRX Latest Social Stream


Loading social stream, please wait...

View Full ACRX Social Stream

Latest ACRX News From Around the Web

Below are the latest news stories about Acelrx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACRX as an investment opportunity.

ACRX Final Deadline Alert: Rosen, Global Investor Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX

New York, New York--(Newsfile Corp. - July 31, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the "Class Period"), of the important August 9, 2021 lead plaintiff deadline.SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out ...

Yahoo | July 31, 2021

AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

Investors with losses are encouraged to contact the firm before August 9, 2021; click here to submit trade information LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation. Investors are encouraged to contact atto

Yahoo | July 30, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX

NEW YORK, NY / ACCESSWIRE / July 30, 2021 / Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ:ACRX) and certain of its officers.

Yahoo | July 30, 2021

ACRX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action – ACRX

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”), of the important August 9, 2021 lead plaintiff deadline. SO WHAT: If you purchased AcelRx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee

Yahoo | July 29, 2021

INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 29, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company') (NASDAQ:ACRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.

Yahoo | July 29, 2021

Read More 'ACRX' Stories Here

ACRX Price Returns

1-mo -11.94%
3-mo -2.48%
6-mo -45.62%
1-year 8.26%
3-year -54.62%
5-year -66.95%
YTD -4.84%
2020 -41.23%
2019 -8.66%
2018 14.07%
2017 -22.12%
2016 -32.47%

Continue Researching ACRX

Want to see what other sources are saying about Acelrx Pharmaceuticals Inc's financials and stock price? Try the links below:

Acelrx Pharmaceuticals Inc (ACRX) Stock Price | Nasdaq
Acelrx Pharmaceuticals Inc (ACRX) Stock Quote, History and News - Yahoo Finance
Acelrx Pharmaceuticals Inc (ACRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8388 seconds.